Is Adagrasib Active in KRAS G12C–Mutated NSCLC?
The oral KRAS G12C inhibitor adagrasib may offer durable clinical activity, with a median overall survival of 14.1 months and a 2-year survival rate of about 33%, in...
Immunotherapy Combination vs Standard Chemotherapy for Metastatic NSCLC
Researchers have discovered that therapy with first-line nivolumab in combination with ipilimumab may improve the 6-year survival and quality...
Does Benzo Type Impact Pancreatic Cancer Outcomes?
Pancreatic cancer has the poorest 5-year survival rate (12.5%) relative to all other cancers. In 2023, about 64,050 people will be diagnosed with pancreatic cancer...
AACR Issues Annual Cancer Progress Report
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)...
FDA Approves New, Updated Indications for Temozolomide
On September 14, the U.S. Food and Drug Administration (FDA) approved updated labeling for temozolomide (Temodar) for the treatment of CNS cancers under...
Noelle K. LoConte, MD: ‘I Want to Kill You’
William K. Oh, MD, and Charles J. Ryan, MD: Prostate Cancer Disparities and the ‘Last Mile’ Problem
Carolina Tannenbaum-Baruchi, PhD: A Call for Tailored Medical Services in Oncology Care for Older Deaf Patients
S. Monica Soni, MD, and Andrew A. Hertler, MD, FACP: Rethinking Prior Authorization
Ernest Hawk, MD, MPH: Lung Cancer Screening and Possible Unappreciated Benefits
Sponsored Content
Sponsored by Bristol Myers Squibb
First-Line Treatment of PD-L1–Negative Non–Small Cell Lung Cancer
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed or Refractory Mantle Cell Lymphoma
Community-Based Engagement Initiative Improves Accrual of Black Participants in Clinical Trials
A 5-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group of patients with...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Sotorasib for KRAS G12C–Mutated NSCLC: Overall Survival and Exploratory Subgroup Analyses
Results from the phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and a median overall survival of 12.5 months in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC)....
Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors
Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
FDA Approves New Pediatric Indication for Technetium Tc 99m Tilmanocept Injection
The Lymphoseek (technetium Tc 99m tilmanocept) injection—a radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies—has been approved for pediatric use by the U.S. Food and Drug Administration (FDA). "This new indication opens the door ...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
